Gene Expression Study and Pathway Analysis of Histological Subtypes of Intestinal Metaplasia that Progress to Gastric Cancer by Companioni, Osmel et al.
RESEARCH ARTICLE
Gene expression study and pathway analysis
of histological subtypes of intestinal
metaplasia that progress to gastric cancer
Osmel Companioni1*, Jose´ Miguel Sanz-Anquela2, Marı´a Luisa Pardo3,
Eulàlia Puigdecanet4, Lara Nonell4, Nadia Garcı´a1, Vero´nica Parra Blanco5,
Consuelo Lo´pez6, Victoria Andreu7, Miriam Cuatrecasas8, Maddi Garmendia9,
Javier P. Gisbert10, Carlos A. Gonzalez1, Nu´ria Sala1*
1 Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Institut Català d’Oncologia,
Barcelona, Spain, 2 Cancer Registry and Pathology Department, Hospital Universitario Prı´ncipe de Asturias
and Department of Medicine and Medical Specialties, Faculty of Medicine, University of Alcala´, Alcala´ de
Henares, Madrid, Spain, 3 Pathology Department, Complejo Hospitalario de Soria, Spain, 4 Microarray
Analysis Service, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain, 5 Department of
Histopathology, Hospital Universitario Gregorio Maraño´n, Madrid, Spain, 6 Department of Pathology,
Hospital Universitario de la Princesa, Madrid, Spain, 7 Department of Gastroenterology, Hospital de
Viladecans, Spain, 8 Department of Pathology, Hospital Clı´nic de Barcelona, Universitat de Barcelona,
Biobanc Clinic IDIBAPS, Barcelona, Spain, 9 Department of Pathology, and Department of
Gastroenterology, Hospital Donostia/Instituto Biodonostia, Universidad del Paı´s Vasco (UPV/EHU),
CIBEREHD, San Sebastia´n, Spain, 10 Gastroenterology Unit, Hospital Universitario de La Princesa and
Instituto de Investigacio´n Sanitaria Princesa (IIS-IP), Centro de Investigacio´n Biome´dica en Red de
Enfermedades Hepa´ticas y Digestivas (CIBEREHD), Madrid, Spain
* nsala@iconcologia.net (NS); osmel.companioni@yahoo.es (OC)
Abstract
Background
Intestinal metaplasia (IM) is a precursor lesion that precedes gastric cancer (GC). There are
two IM histological subtypes, complete (CIM) and incomplete (IIM), the latter having higher
progression rates to GC. This study was aimed at analysing gene expression and molecular
processes involved in the progression from normal mucosa to IM, and also from IM subtypes
to GC.
Methodology
We used expression data to compare the transcriptome of healthy gastric mucosa to that of
IM not progressing to GC, and the transcriptome of IM subtypes that had progressed to GC
to those that did not progress. Some deregulated genes were validated and pathway analy-
ses were performed.
Results
Comparison of IM subtypes that had progressed to GC with those that did not progress
showed smaller differences in the expression profiles than the comparison of IM that did not
progress with healthy mucosa. New transcripts identified in IM not progressing to GC
included TRIM, TMEM, homeobox and transporter genes and SNORD116. Comparison to
normal mucosa identified non tumoral Warburg effect and melatonin degradation as
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previously unreported processes involved in IM. Overexpressed antigen processing is com-
mon to both IM-subtypes progressing to GC, but IIM showed more over-expressed onco-
genic genes and molecular processes than CIM.
Conclusions
There are greater differences in gene expression and molecular processes involved in the
progression from normal healthy mucosa to IM than from IM to gastric cancer. While antigen
processing is common in both IM-subtypes progressing to GC, more oncogenic processes
are observed in the progression of IIM.
Introduction
Gastric carcinogenesis proceeds through a series of precursor lesions in the gastric mucosa
named the Correa´s cascade, constituted by multi-atrophic gastritis, intestinal metaplasia (IM)
and dysplasia conducting to gastric cancer (GC) [1]. In this process, IM is a crucial lesion, due
to its high progression rate to GC (3.77/1000 person-years, in the province of Soria, Spain) [2].
IM is a trans-differentiation process of the gastric epithelium to an intestinal type, mostly
induced by H.pylori infection and expression of the homeobox genes CDX1 and CDX2. It is a
protective response against inflammation but it also increases the risk of neoplastic transfor-
mation [3].
Intestinal metaplasia has been histologically divided in two types. The complete (CIM, type
I, small intestine) is characterized by goblet, absorptive enterocytes and Paneth cells. The
incomplete (IIM, types II and III, colonic) is characterized by the presence of goblet and hybrid
columnar intermediate cells, absence of enterocytes and rare presence of Paneth cells [2]. Fol-
low-up epidemiologic studies show a higher progression rate to GC of incomplete compared
to the complete type of IM [4]. Clinical management guidelines recommend gastroscopy every
3 years when extensive IM is present [5]. However, only a minority of patients with this lesion
develop GC [4] and the genes and pathways responsible for this progression are unknown.
Therefore, the identification of deregulated genes and molecular processes responsible for this
transition is relevant because it could reveal driver genes for tumor progression as well as
potential new biomarkers and therapeutic targets.
Gene expression profiling of IM has identified an up-regulation of intestinal differentiation
[6,7] and lipid metabolism [6,7,8] genes. However, to our knowledge, there are no published
studies comparing samples of IM that progress to gastric cancer along time with those that do
not progress. Our hypothesis is that some genes and molecular processes are deregulated in
complete and incomplete IM that progress to gastric cancer (CIM-GC and IIM-GC). To test
this, we performed expression profiling to compare mRNA from histological subtypes of IM
that after a follow-up study had progressed to GC (CIM-GC and IIM-GC) with the mRNA
from those IM subtypes that did not progress to GC (CIM-NoGC, IIM-NoGC). Normal gastric
mucosa was also compared to IM subtypes that did not progress to GC (IM-NoGC).
Materials and methods
Patients and samples
Samples were obtained from two Spanish follow-up studies of gastric carcinogenesis. One was
performed in the province of Soria [2] and the other was a multicenter study including 9
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Spanish hospitals [9]. Furthermore, samples from the Gregorio Maraño´n´s hospital, in
Madrid, were also included. Patients diagnosed at recruitment with CIM and IIM were sub-
jected to a new gastroscopy after a mean follow-up of 12 ±3.4 years.
As previously published, formalin-fixed paraffin-embedded (FFPE) samples at recruitment
and at the end of follow-up were diagnosed by histology [2,9]. Briefly, 3–4 biopsies from the
antrum, incisura or corpus, were stained with hematoxylin–eosin, Alcian blue–periodic acid
Shiff (AB-PAS, pH 2.5) and Giemsa. Additionally, for some IIM samples, some sections were
stained with high-iron diamine–Alcian blue to detect sulfated mucins [2]. Complete IM was
classified by the presence of brush border cells and goblet cells, but without non-goblet and
hybrid columnar ‘‘intermediate” cells. Incomplete IM, which also contains goblet cells, was diag-
nosed by the presence of its predominant cell type, the hybrid ‘‘intermediate” non-goblet
mucous columnar cells. This hybrid mucous cell is easily identified because they show, with the
mucino histochemical AB-PAS, a mixed gastric and intestinal phenotype pattern: red for neutral
gastric mucins and blue for a combination of intestinal mucins [2].Two pathologists (MLP and
JMSA) reviewed the biopsies of all the included cases. Furthermore, when FFPE blocks were cut
for RNA extraction (see below) additional hematoxylin-eosin staining was performed at initial
and final cuts to confirm that the tissue in between was from the corresponding IM subtype.
All samples used in this study were obtained from projects approved by the Ethics commit-
tee of the Biomedical Research Institute of Bellvitge (CEIC HUB-ICO-IDIBELL), as well as
those of the hospitals involved in the projects FIS Exp PI030077 (Hospital de Soria), FIS
ExpPI10/01089, PI10/01031 and PI10/01203 and the Gregorio Maraño´n hospital.
RNA extraction and microarray analysis
Total RNA was extracted from FFPE cuts of gastric biopsies at recruitment. An initial and a
final slide for Hematoxylin-Eosin (HE) staining was obtained and evaluated before RNA
extraction in order to further confirm the lesion-type and to select those samples that con-
tained at least 50% of IM in all cuts. RNA was obtained from 8 CIM-GC, 6 IIM-GC, 9 CIM--
NoGC, 7 IIM-NoGC, and 15 normal gastric mucosae. We selected FFPE blocks of IM (IIM or
CIM)-GC patients of similar sex and age as IM (IIM or CIM)-NoCG patients. The characteris-
tics of the patients’ samples are shown in S1 Table.
Total RNA was extracted with Recover All Nucleic Acid for FFPE kit (Ambion, USA). RNA
quality was evaluated using NanoDrop 2000 (Thermo Scientific, USA) for quantification and
purity check, and using the Bioanalyzer 2100 (Agilent Technologies, USA) for RNA integrity
analysis. For microarray analysis, 100ng of input RNA from each sample was processed using
the SensationPlus FFPE Amplification and 3’IVT Labeling Kit (Affymetrix, USA) and hybrid-
ized to the Almac Xcel array (Affymetrix, USA), specifically optimized for use with degraded
FFPE samples.
Quality control, statistical and bioinformatics analyses
After quality assessment, data normalization was performed by the Robust Multichip Analysis
method (Affymetrix1 Expression Console™ Software) [10] to correct background, apply quan-
tile normalization and summarize all the probes of a transcript in logarithmic base 2. Batch
effect was corrected by method Combat [11]. Of the initial 81.804 probe sets, we selected
57.263 above the 30 percentile to eliminate noise produced by probes that do not express
enough intensity/signal. A dendrogram representation of the sample hierarchical clustering
was constructed using the Euclidean distance and method Complete.
Differentially expressed genes were obtained by moderated t test for microarray data
(Limma) [12] and adjusted by False Discovery Rate (FDR) [13]. Three types of comparisons
Intestinal metaplasia progression to gastric cancer
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were performed: IIM-GC vs IIM-NoGC, CIM-GC vs CIM-NoGC and IM-NoGC vs Healthy
mucosa. In order to exclude potential tumoral processes, in the comparison of IM with healthy
mucosa we did not include IM samples that had progressed to GC. Genes were considered dif-
ferentially expressed if the t-test p-value was <0.05 and the fold change (FC)2 (up-regulated)
or0.5 (down-regulated). Differences between the analyzed groups in clinical and morpho-
logical variables of the study patients (age, sex, H.pylori infection status and anatomical loca-
tion of the lesion in the stomach) were analyzed by means of the t-test for continuous variables
and the Fisher exact test for categorical variables. Significant differences (p<0.05) were only
obtained for age between IM-NoGC group and healthy mucosa. In agreement with the age
and sex matched selection of FFPE blocks from IM-GC and IM-NoGC patients, no age differ-
ences were observed between the different groups of intestinal metaplasia (IIM or CIM)
patients. There were also no differences between groups for any of the other variables analyzed.
Thereafter, p-values for moderated t test were only age adjusted in the comparisons IIM-GC
vs Healthy, IIM-NoGC vs Healthy, CIM-GC vs Healthy, CIM-NoGC vs Healthy, IM-NoGC vs
Healthy and IM-GC vs Healthy. Analyses were performed with R (v3.1.1) and Bioconductor
[14] packages. Data are accessible in GEO (GSE78523).
We constructed Venn diagrams (http://bioinformatics.psb.ugent.be/webtools/Venn/) to
identify the Differentially Expressed Genes (DEGs) that were unique or common to the differ-
ent IIM and CIM analysis groups (IIM-GC vs IIM-NoGC, IM-GC vs Healthy mucosa and
IM-NoGC vs Healthy mucosa; and the same for CIM) and to select DEGs specific for IIM-GC
vs IIM-NoGC and IIM-GC vs Healthy comparisons, but absent in IIM-NoGC vs Healthy.
We used the GEO2R tool of Gene expression Omnibus (https://www.ncbi.nlm.nih.gov/
geo/) to analyze the deposited GEO data from a similar study (GSE69146) [15] and to compare
with our results.
Gene Set Enrichment Analysis, GSEA
Normalized expression values were loaded to GSEA [16] and the gene set collections c2.all.
v5.0 and c3.tft.v5.0 of MSigDB v5.0 [16] were interrogated. c2.all.v5.0 includes gene sets from
signaling pathways and genetic or chemical perturbations, while c3.tft.v5.0 contains genes that
share a transcription factor binding site in TRANSFAC v7.4. The default parameters were
applied with the exception of IIM-GC vs IIM-NoGC where permutations were performed on
Gene set following methodology recommendations [17]. A gene set was considered significant
if the p-value was<0.05 and q-value was <0.25 for CIM-GC vs CIM-NoGC and IM-NoGC vs
Healthy. However, for IIM-GC vs IIM-NoGC a gene set was considered significant if the nom-
inal p-value was<0.01 and the q-value was<0.05 to avoid the higher rate of false positives typ-
ically encountered when gene sets are used for permutation [18].
We categorized gene sets to molecular processes according to their functions (e.g. COL-
LER_MYC_TARGETS_UP (oncogenes)). Furthermore, we looked at the intersections
between: A) gene sets with enrichment scores (ES) higher than cutoffs (IIM-GC: ES>0.5,
IM-NoGC: ES>0.65), B) extreme values of “Rank at max” parameter and C) leading edge
genes that are also DEGs [17].
An expression dataset of IM and healthy gastric mucosa [19] deposited in Gene Expression
Omnibus (GSE47797) was downloaded and analyzed by GSEA following the previous
methodology.
Ingenuity Pathway Analysis (IPA)
The default Core Analysis of IPA [20] was used to identify biological processes, functions,
canonical pathways and molecular networks from differentially expressed genes in the three
Intestinal metaplasia progression to gastric cancer
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specified comparisons. This software compares DEGs from an experiment against genes col-
lected in the Ingenuity1 Knowledge base. In this way, canonical pathways and molecular net-
works are identified, providing insight of how DEGs interact [20]. Results with p-value<0.05
were considered significant.
Validation by RT-qPCR of differentially expressed genes
Validation of 19 DEGs from the microarray was performed by RT-qPCR using the dynamic
expression arrays Biomark HD 96x96 (Fluidigm, USA) and UPL probes (Roche, Switzerland).
The RT-qPCR protocols (PN 68000116 B3, PN-100-6472 A1, PN 100–5876 B1 and PN
68000130 E1) of Fluidigm were followed. We selected some top up and down-regulated signifi-
cant genes of interest from Tables 1–3 (S2 Table) and performed duplicated qPCR in CIM-GC
(N = 24), CIM-NoGC (N = 33), IIM-GC (N = 11), IIM-NoGC (N = 8) and Healthy (N = 16)
Table 1. Differentially expressed genes with oncogenic functions in the IIM progressing to GC (IIM-GC).
Gene Symbola Function Fold Change Nominal p-value Associated with gastric carcinogenesisb
IK Antigen Processing 0.384 0.002 New
HLA-A 2.059 0.029 Yes [23]
HLA-DQB1 2.17 0.001 Yes [24]
CD24 2.249 0.008 Yes [25]
HLA-DRB4 2.25 0.024 Yes [24]
HLA-DQA1 3.182 0.024 Yes [24]
HLA-DRB1/3/5 3.368 0.048 Yes [24]
HLA-C 4.417 0.011 Yes [26]
CXCL14 Inflammation 2.007 0.028 Yes, GC prognosis [27]
IL1R2 2.31 0.019 New
BPIFB1 2.866 0.009 New
C1R Complement system 2.048 0.005 New
C1QBP 2.076 0.002 New
C3 2.193 0.020 New
PPIA Chaperones 0.393 0.027 Yes [28]
CCT6A 2.053 0.002 New
CANX 2.117 0.027 New
HSP90AA1 2.412 0.0001 Yes, GC prognosis [29]
HSP90AB1 2.479 0.003 Yes, GC prognosis [29]
RBBP7 Tumor suppression 0.449 0.001 New
EIF5B 2.059 0.004 New
CAV1 2.144 0.0005 YES, GC metastasis [30]
EIF3D 2.211 0.003 New
CDKL3 Cell cycle regulator 0.403 0.0001 New
CP Metabolism of iron 0.412 0.040 Yes, decreased in GC [31]
MYOF Angiogenesis 2.035 0.006 New
ANP32B Anti-apoptotic factor 2.155 0.006 New
NHP2 Telomerase 2.187 0.002 Yes, GC prognosis [32]
GNL3 Stem cell proliferation 2.218 0.0003 New
RAN Oncogene 2.41 0.004 Yes, SNPs associated [33]
a Genes are ordered increasingly according to Fold Changes inside the functional groups.
b It refers to genes previously associated with gastric carcinogenesis by genetic association, expression, proteomic or functional studies. IIM, Incomplete
Intestinal Metaplasia. GC, Gastric cancer
https://doi.org/10.1371/journal.pone.0176043.t001
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samples. Some of these samples were the same as those used for the microarray analysis (S1
Table); the remaining samples were from an independent series (S3 Table).
ACTB, GAPDH, G6PD, RPL29 and B2M genes were considered as potential reference genes
due to their lack of significance in the microarray analysis. The selected reference gene was
ACTB, which was the one that exhibited the lowest significance by ANOVA (p-value = 0.395),
when comparing Ct values of IM-GC vs IM-Not CG vs Healthy controls, using the software
GraphPad Prism v5.01 [21]. The expression levels of the target genes and their statistical signif-
icance were calculated by use of the Bootsratio software [22] after introduction of 2-ΔCt values
for cases and controls, where ΔCt = Ct mean(target gene)-Ct mean (ACTB). In all cases a p-
value<0.05 was considered significant.
Results
Hierarchical clustering and principal component analysis of the analysed samples based on the
gene expression profiles obtained after microarray analysis showed a clear separation between
healthy controls and all the IM samples; however, little differences between IM samples that
had progressed to GC with respect to those that did not progress were observed (Fig 1). A simi-
lar representation of the data was observed in the heatmaps of the compared groups (Fig 2).
Differentially expressed genes were observed from the three comparisons, but the differences
between IM (either IIM or CIM)-GC and (IIM or CIM)-NoGC were not significant after
applying the FDR test.
IIM-GC vs IIM-NoGC: 106 genes were identified as differentially expressed, of which
75.4% were over-expressed and 24.6% under-expressed in the IIM-GC (S4 Table).
CIM-GC vs CIM-NoGC: 19 genes were differentially expressed, being the majority
(N = 11) under-expressed in the CIM-GC (S5 Table).
To select tumour progression genes specific for the IMs-GC, we compared the DEG of IM
(IIM and CIM) that progressed to GC versus those that did not progress with the DEG in the
IMs that did not progress versus healthy mucosa and those in the IMs that progressed to GC
versus healthy mucosa (Fig 3). Among the genes specific of IIM or CIM progression to GC,
there were more deregulated transcripts with oncogenic functions in the IIM-GC (Table 1)
than in the CIM-GC (Table 2).
IIM vs CIM: Comparison of IIM-GC vs CIM-GC revealed 17 DEGs (p-val<0.05), of which
15 were upregulated and 2 were downregulated (S6 Table), but as in the comparisons of
Table 2. Differentially expressed genes with oncogenic functions in the CIM progressing to GC (CIM-GC).
Gene Symbola Function Fold Change Nominal p-value Association with gastric carcinogenesisb
IGHG1/IGHM/ IGHV4-31 Antigen Processing 0.493 0.014 YES
HLA-DRB4 2.049 0.022 YES [24]
HLA-DRB1/3/5 3.475 0.021 YES [24]
ANAPC5 Mitotic factor 0.461 0.031 New
IL1R2 Inflammation 0.475 0.017 New
PRSS1 Protein degradation 0.495 0.033 New
GP2 Innate immunity response 2.063 0.018 New
HOXA13 Intestinal differentiation 2.076 0.028 YES [34]
IGFBP5 Cellular proliferation 2.127 0.004 New
OLFM4 Antiapoptotic factor 3.332 0.0002 YES [35]
a Genes are ordered increasingly according to Fold Changes inside the functional groups.
b It refers to genes previously associated with gastric carcinogenesis by genetic association, expression, proteomic or functional studies. CIM, Complete
Intestinal Metaplasia. GC, Gastric cancer
https://doi.org/10.1371/journal.pone.0176043.t002
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IIM-GC vs IIM-NoGC and CIM-GC vs CIM-NoGC, none of them was significant after FDR
adjustment for multiple comparisons (FDR). Nevertheless, it is to note the increased expres-
sion in IIM-GC of immunoglobulin and inflammatory gene products, indicating an increased
active immunoinflammatory response in IIM-GC. There was also an increased expression in
IIM-GC of some key molecules in the gastric function such as pepsinogen, H+/K+ channel
generator of the H+ ion for HCl synthesis and gastric intrinsic factor.
Comparison of IIM-NoGC vs CIM-NoGC revealed 16 DEGs (p-val<0.05), of which four
DEGs were upregulated and 11 were downregulated (S7 Table); again, none of them was
Table 3. Differentially expressed genes representative of molecular processes in the IM not progressing to GC (IM-NoGC).
Gene Symbola Functionb Fold Change p-value Adj p-value
CDX2 Intestinal differentiation 3.133 4.050E-11 2.343E-08
CDX1 4.147 3.523E-09 1.187E-06
HOXB13 Intestinal differentiation (New DEGs) 2.099 2.508E-04 1.187E-02
HOXB6 2.884 2.313E-07 4.386E-05
HOXA13 3.294 7.134E-05 4.632E-03
MUC3A Mucins 13.277 1.677E-16 6.001E-13
MUC12 16.382 4.336E-09 1.395E-06
MUC17 15.579 1.550E-15 3.773E-12
MUC2 24.748 5.216E-25 1.857E-20
APOA1 Lipid Metabolism 7.146 4.060E-07 6.902E-05
APOA4 7.331 2.059E-08 5.385E-06
MTTP 23.334 1.176E-14 1.871E-11
APOB 35.139 5.209E-15 9.479E-12
FABP1 67.381 7.752E-25 1.857E-20
CYP3A4 Xenobiotic Metabolism 7.304 4.204E-08 1.003E-05
UGT2A3 2.741 9.798E-06 9.690E-04
GSTA1 3.285 2.794E-04 1.287E-02
GAST Hipoclorhidria 6.249 4.603E-10 2.075E-07
SST 0.183 1.815E-08 4.789E-06
SLC46A3 Transporters (New process) 5.553 1.458E-10 7.258E-08
SLC7A9 6.007 7.421E-11 4.047E-08
SLC17A4 7.240 3.905E-12 3.105E-09
SLC5A1 8.238 2.024E-09 7.492E-07
SLC13A2 8.412 2.326E-14 3.330E-11
SLC6A19 9.009 1.581E-15 3.773E-12
SLC26A3 16.877 3.539E-11 2.136E-08
TRIM15 NFKB activation(New DEGs) 2.256 4.063E-07 6.902E-05
TRIM31 2.372 8.101E-06 8.298E-04
TRIM36 2.548 3.530E-07 6.125E-05
TRIM40 2.677 1.287E-04 7.379E-03
SNORD116s Expression regulators (New process) 0.443 1.378E-04 7.675E-03
TMEM25 TMEM function (New process) 2.768 1.617E-04 8.622E-03
TMEM139 3.386 2.229E-10 1.064E-07
TMEM45B 2.709 1.380E-09 5.450E-07
DMBT1 Tumor suppressor 71.951 9.727E-25 1.857E-20
a Genes are ordered increasingly according to Fold Changes inside the functional groups.
b New means that novel DEGs or molecular processes were found. IIM, Incomplete Intestinal Metaplasia. GC, Gastric cancer
https://doi.org/10.1371/journal.pone.0176043.t003
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Fig 1. Dendrogram and principal component analysis of the analysed samples. A) Dendrogram
showing the hierarchical clustering of the analysed samples. Clustering was based on the overall gene
expression values of the studied groups. B) Principal Components Analysis.
https://doi.org/10.1371/journal.pone.0176043.g001
Fig 2. Heat maps of the analyzed groups. A) IIM-GC vs IIM-NoGC, B) CIM-GC vs CIM-NoGC, C) IM-NoGC vs Healthy.
https://doi.org/10.1371/journal.pone.0176043.g002
Fig 3. Venn diagrams of the differentially expressed genes in three different comparisons. A,
Incomplete intestinal metaplasia. B, Complete intestinal metaplasia. IIM-GC or CIM-GC, incomplete or
complete intestinal metaplasia progressing to gastric cancer. IIM-NoGC or CIM-NoGC, incomplete or
complete intestinal metaplasia not progressing to gastric cancer. Healthy, healthy gastric mucosa.
https://doi.org/10.1371/journal.pone.0176043.g003
Intestinal metaplasia progression to gastric cancer
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significant after FDR adjustment. Five of these DEGs were the same as in IIM-GC vs CIM-GC
but four of them (CXCL17, PGC and two corresponding to IGH genes) were upregulated in
IIM-GC and downregulated in IIM-NoGC, while EBF1was downregulated in both comparisons.
IM-NoGC vs Healthy: We identified 482 DEGs (394 upregulated and 88 downregulated),
all of which significant after FDR test. With respect to previous comparisons it is relevant to
note the higher number of both DEGs and expression levels (FC>4 N = 92) and that they are
all significant after FDR (S8 Table). DEGs contributing to molecular processes previously
reported in IM were confirmed and new genes contributing to these processes as well as to
new processes were also identified (Table 3).
Gene Set Enrichment Analysis (GSEA)
From the c2all.v5 gene set collection we obtained 144 gene sets significantly over-expressed
in the IIM-GC. From the c3tft.v5 collection we obtained 19 overexpressed gene sets, all com-
posed by E2F translation initiation factors. The S9 Table indicates the number of significant
gene sets per molecular process after categorization according to their function. To select the
most relevant molecular processes represented by these gene sets, cut-offs to Rank at max
and ES parameters were applied and up-regulated leading edge genes were identified (S11
and S12 Tables). Comparison of these results with those of the gene sets with enrichment
scores above 0.5 indicated that activation of cell cycle and cell proliferation, oncogenes,
tumor suppressors and insulin regulated genes were important processes in the progression
of IIM to GC (Fig 4A).
For the CIM-GC group we only obtained two significant gene sets (GAZDA_DIAMOND_-
BLACKFAN_ANEMIA_ERYTHROID_UP, REACTOME NETRIN1_SIGNALING) without
any apparent relationship with gastric carcinogenesis.
When both IM subtypes that do no progress to GC were grouped and compared with
healthy mucosa, 120 gene sets grouped in different molecular processes were over-expressed
in IM-NoGC (S10 Table). There were 12 over-expressed gene sets from the c3.tft.v5.0 cata-
logue composed by transcription factors HNF1/4 and GATA1/6, which cooperate to induce
intestinal genes [3].
When we compared the relevant molecular processes in IM-NoGC, following identical
methodology as indicated for IIM-GC (S13 and S14 Tables), the most important processes
were found to be Warburg effect, lipid metabolism, intestinal differentiation, aberrant glyco-
sylation, antigen processing, inflammation and apoptosis (Fig 4B).
Ingenuity Pathway Analysis (IPA)
The IPA analysis showed that, unlike to the GSEA, there were several up-regulated pathways
common to the IIM-GC and CIM-GC such as antigen presentation, signaling by TNFRSF4,
Fig 4. Venn´s diagram to select the most relevant molecular processes after GSEA analyses. A,
Incomplete intestinal metaplasia progressing to gastric cancer (IIM-GC). B, Both types of intestinal metaplasia
not progressing to gastric cancer (IM-NoGC).
https://doi.org/10.1371/journal.pone.0176043.g004
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communication between innate and adaptive cells, maturation of dendritic cells and the possi-
ble role of other homeobox genes such as HOXC11 in the development of the intestinal differ-
entiation. Due to the small number of differentially expressed genes in CIM-GC (Table 2),
pathways over-expressed in this group were composed by a small number of genes and of
lower statistical significance, when compared with the IIM-GC group (Table 4). Regarding
IM-NoGC, IPA confirmed the GSEA results for metabolism of lipids and xenobiotics and a
previously observed deregulation of the thyroid hormone metabolism. A new process of mela-
tonin degradation was also identified (Table 4).
The molecular network with highest score in the IIM-GC was found to be composed of
effectors of the immune response such as HLA class I (HLA-A, HLA-C) and II (DQB1, DRB1)
molecules, the cytokine receptor IL1R2, immunoglobulins, and oncogenic molecules such as
the chaperones CANX and HSP90AA1 and the tumor suppressor CAV1 (S1 Fig). There was
not a high score molecular network in CIM-GC. The molecular network with the highest
score in the IM-NoGC includes the processes of lipid metabolism, molecular transport and
biochemistry of small molecules (S2 Fig).
Validation of DEGS from microarray results by RT-qPCR
RT-qPCR was used to validate selected DEGs obtained in the IIM-GC (N = 7), CIM-GC
(N = 4) and IM-NoGC (N = 11) groups (S2 Table). Only 51% of reactions passed the quality
control defined by the Fluidigm software, probably reflecting RNA degradation. Of the 19
DEGs selected from the microarray, 9 were also differentially expressed in the qPCR, but only
Table 4. Over-expressed canonical pathways and other information from Ingenuity Pathway Analysis.
Group Canonical pathway p-value Upstream
Regulators
Diseases Cellular and molecular functions
IIM-GC Antigen presentation 3.15E-10 HOXC11
RAD21
EBI3
NLRC5
SMC3
-Immunological
-Connective Tissue
-Inflammatory
-Muscular and
Skeletal
-Development
-Cell proliferation
-Cell death and survival
-Cellular movement
-Cellular development
-Cell-cell interaction and signaling
IIM-GC TNFRSF4 (OX40) signaling 3.27E-09
IIM-GC Thyroid autoimmune disease 1.66E-08
IIM-GC Development of B cells 1.51E-07
IIM-GC Maturation of dendritic cells 1.26E-06
IIM-GC Phagosome maturation 1.59E-06
IIM-GC Communication between innate and
adaptive cells
1.62E-06
CIM-GC Communication between innate and
adaptive cells
3.14E-05 LGALS3
LHCGR
MYBL2
mir-296
CHI3L1
-Endocrine
-Gastrointestinal
-Immunological
-Inflammatory
-Development
-Cell-cell interaction and signaling
-Cellular movement
-Cell death and survival
-Cell cycle
- Cellular assembly and organization
CIM-GC Maturation of dendritic cells 3.22E-04
CIM-GC Antigen presentation 3.98E-04
CIM-GC TNFRSF4 (OX40) signaling 7.49E-04
IM-NoGC Activation of FXR/RXRG 1.42E-08 HNF4A
HNRNPA2B1
HNF1A
CTNBB1
SREBF1
-Endocrine
-Metabolism
-Gastrointestinal
-Hepatic
-Cardiovascular
-Cellular movement
-Death and cell survival
-Lipid metabolism
-Molecular transport
-Biochemistry of small molecules, drugs and
amino acids
IM-NoGC Activation of PXR/RXRG 1.34E-07
IM-NoGC Inhibition of RXRG by LPS/IL1 2.24E-05
IM-NoGC Development of B cells 7.76E-05
IM-NoGC Degradation of sucrose 4,30E-05
IM-NoGC Metabolism of thyroid hormone 0.0004
IM-NoGC Hematopoiesis of stem cells 0.0005
IM-NoGC Activation of LXR/RXR 0.0006
IM-NoGC Degradation of melatonin (New) 0.0013
IM-NoGC Glycolysis I 0.0039
IM-NoGC Xenobiotic Metabolism Signaling 0.0052
https://doi.org/10.1371/journal.pone.0176043.t004
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in 7 of them (36.84% of total DEGs) the difference in expression had the same direction (Fig
5). One of the validated genes both in CIM-GC and IMM-GC is HLA-DRB4, which is in agree-
ment with the fact that antigen presentation is a molecular process common to the progression
of both IM subtypes in the GSEA and IPA analyses. Also, the highest up-regulated gene in
CIM-GC, OLFM4, was validated.
Discussion
As far as we know, this is the first study on differential gene expression between IM subtypes
that have progressed to gastric cancer and those who have not progressed, after a several years
follow-up period. Our results from gene expression and pathway analysis indicate that
IM-NoGC is very different from healthy gastric mucosa but the differences between IM sub-
types that progress to GC and those that do not progress are smaller and of lower magnitude.
Despite this general finding, we have identified DEGs and molecular processes involved in the
progression from IM subtypes to gastric cancer. Furthermore, we have confirmed previously
reported molecular processes that distinguish IM from healthy gastric mucosa and have identi-
fied new transcripts contributing to these processes.
Fig 5. Validation by RT-qPCR of some differentially expressed genes obtained in the microarray analysis. Comparison of the expression level
(fold change) by microarray analysis and by RT-qPCR of significant differentially expressed genes in the IIM-CG versus IIM-NoGC, CIM-GC versus
CIM-NoGC and IM-NoGC versus healthy gastric mucosa.
https://doi.org/10.1371/journal.pone.0176043.g005
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Although expression differences were not found significant after multiple corrections when
IIM-GC was compared to IIM-NoGC, some of the DEGs have been previously associated with
gastric carcinogenesis. There are several up-regulated transcripts reflecting the inflammatory
process induced by H. pylori infection, such as HLA-A, HLA-C [26], HLA-DRB1/3/5,
HLA-DQA1/DQB1 [24, 36]. It is interesting to note that HLA-DRB is up-regulated in both
IIM-GC and CIM-GC, that HLA-DRB4 overexpression was confirmed by RT-qPCR and that
antigen presentation also is a common pathway in both IM-subtypes progressing to GC, alto-
gether being in agreement with the immune response as an important process in the progression
of precursor lesions to GC [37]. There are several up-regulated inflammatory transcripts
(CXCL14, IL1R2, BPIFB1) and also from the complement system (C1R,C1QBP, C3) which
increase inflammation and phagocytosis of bacteria, respectively. Regarding this, other comple-
ment components such as C1S,C1QR1 and CD55 have been found over-expressed in GC [38].
Several chaperones responsible for proper oncoproteins folding were found overexpressed, such
as CCT6A,CANX,HSP90AA1 and HSP90AB1. Interestingly, over-expression of HSP90AA1 and
HSP90AB1 has been associated with poor prognosis in GC [29]. The regulators of the tumor
suppressor RB1, EIF3D and EIF5Bwere also found over-expressed, as well as NHP2, a telome-
rase whose high expression in GC is correlated with poor clinical prognosis [32]. A member of
RAS oncogenes called RAN, with genetic polymorphisms associated with of GC risk [33], was
also found overexpressed. Novel over-expressed genes not previously associated with gastric car-
cinogenesis are MYOF, an angiogenesis regulator [39], and GNL3, that interacts with TP53 and
may be involved in carcinogenesis because of its role in cancer and stem cells proliferation [40].
Apart from the above mentioned overexpression of HLA-DRB, in the CIM-GC group there
were fewer significant transcripts than in IIM-GC. Furthermore, it is to note the increased
expression in IIM-GC of immunoglobulin (IGHG, IGHM) and inflammatory (CXCL17) gene
products, indicating an increased active immunoinflammatory response in IIM-GC when com-
pared to CIM-GC. All these results are in agreement with the increased progression risk to GC of
IIM compared with CIM [4]. It is likely that oncogenic pathways only become activated after
CIM progresses to IIM along the Correa´s cascade. Among the over-expressed genes with onco-
genic functions in CIM-GC there are OLFM4 (olfactomedin 4), whose overexpression was vali-
dated by RT-qPCR, and IGFBP5, an anti-apoptotic and a cell proliferation factor, respectively.
OLFM4 is increased in early stages of gastric carcinogenesis and a prognostic marker for
advanced GC [35]. OLFM4 has also been found to promote tumor growth in pancreatic cancer
[41], altogether suggesting that it could be an early factor of gastric tumor progression from CIM.
Confirmation of our main gene expression results through immunohistochemistry would
be the best proof of their validity. Unfortunately, we had no more FFPE sections for further
immunohistochemical staining. Therefore, to further validate our results by comparison with
other available datasets from similar studies, we have searched PubMed and the Gene Expres-
sion Omnibus (GEO) databases for microarray studies exploring the same or similar progres-
sion phenotype. We found a recent study (GEO accession: GSE69144) that used microarray
analysis to determine gene expression changes in the progression along the gastric precancer-
ous cascade of gastric lesions, in H.pylori infected subjects followed for a period of 6 years [15].
However, comparison of this study with ours is difficult because of clear differences in study
design and microarray platform used. While this study was designed for the identification of
changes in gene expression after lesion progression or regression, our study was designed for
the identification of biomarkers of progression to GC at baseline samples. Furthermore, in our
study we analyzed a high-density transcriptome based microarray containing 97,000 tran-
scripts, while Garay et al. used a Cancer Panel Array restricted to 502 genes. Therefore, only
two of the differentially expressed genes of interest in IM progressing to GC in our study
(Tables 1 and 2) were also present in the GSE69144 dataset: CAV1 and IGFBP5. Comparison
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with the GEO2R tool of those baseline samples of the Garay study that had progressed with
those that did not change revealed that IGFBP5 is found similarly overexpressed as in the com-
parison of CIM-GC vs CIM-NoGC in our study. This gene has also been reported to be up-
regulated in gastric cancer [42]. CAV1 was not significant in Garay’s study.
To characterize the transcriptional profile of IM in comparison to healthy gastric mucosa,
we analyzed samples of both histological subtypes that do not progress to GC because these are
more common and also to exclude tumorigenic processes from the analysis. Unlike previous
comparisons, DEGs in IM were significant after multiple comparisons and exhibited greater
expression differences. There are many DEGs previously found up-regulated in IM, such as
CDX2, KRT20, MUC13,OLFM4, REG4 [43], FABP1, MEP1B, SI, SLC6A19 [44], CDX1, MTTP,
CEACAM6 [6], APOA1, APOA4, APOB, CDH17, CLDN3, HNF4A, VIL1 [7]. Their functions
show that intestinal differentiation, metabolism of lipids and xenobiotics, and hypoclorhidria,
characterize the IM. New DEGs identified in the IM-NoGC group reveal the role of other
homeobox genes (HOXA13/B6/C) in the intestinal differentiation, transporters of the solute
carrier family (SLC), NFKB activators (TRIM), small nucleolar RNAs (SNORD116) and
TMEM proteins of unknown function. The highest over-expressed gene is DMBT1 (S6 Table),
a GC tumor suppressor and immunohistochemical marker of IM [45]. It may be speculated
that its high expression could be an early defense mechanism against a potential oncogenic
deregulation along time.
The results from GSEA also showed a difference between IIM-GC and CIM-GC; in the first
group there were many over-expressed gene sets with oncogenic functions, while none was
identified in the CIM-GC. The most relevant molecular processes in IIM-GC are antigen pro-
cessing, inflammation, activation of cell cycle and cell proliferation, oncogenes and tumor sup-
pressors. Other published molecular processes support these differences between the IM
subtypes, indicating that IIM is a more advanced state than CIM along the Correa´s cascade
[1]. Thus, when compared to CIM, IIM has decreased expression of CDX2 [46], less activation
of Sonic Hedgehog pathway [47], higher microsatellite instability [48], increased telomerase
activity [49] and increased intracellular localization of H.pylori [50].
Regarding the IM-NoGC group, among the most relevant processes we found the War-
burg effect, which consists that in tumoral processes glycolysis is increased with respect to
oxidative phosphorylation [51] [52]. In IM-NoGC there is an over-expression of glucose
transporters SLC2A5, SLC5A9, the glycolytic enzyme hexokinase and glucagon, a promoter
of gluconeogenesis. The final product of glycolysis, lactate, activates the hypoxia inducible
factors HIF1A and HIF2A, which induce glycolytic genes [52], and in this regard there are
two over-expressed HIF1A gene sets. Warburg effect is universal in normal cells under active
proliferation to protect them from genomic damage [52], and this could be its role in
IM-NoGC. As already indicated by the DEGs analysis, other relevant processes in IM-NoGC
were found to be lipid metabolism and the O-glycosylation of mucins. During active cell pro-
liferation, biological membranes with high lipid contents, are synthesized for new cells [53].
Besides, since lipids are used as a gluconeogenic energy source, increased lipid metabolism
could be at least in part a consequence of Warburg effect. Mucins are major components of
gastric mucus, with high O-glycosylation contributing to mucosa protection from bacterial
infections. H.pylori modulates glycosylation to create a micro-environment favorable to
infection. In the IM, aberrant glycosylation of MUC5AC and MUC6 increase their hydroso-
lubility [54], maybe allowing penetration of H.pylori in the gastric mucosa and hence increas-
ing inflammation [50].
The consistency of our results is also indicated by the general agreement obtained when we
compared by GSEA the expression profile of IM-NoGC with the raw data of a microarray
expression dataset of IM and healthy gastric mucosa performed by Hanada et al [19] and
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deposited in GEO. As in our study, major biological processes over-expressed in that study
were non tumoral Warburg effect, lipid metabolism, intestinal differentiation, transcription
factors HNF1A/4A, inflammation, aberrant protein glycosylation, apoptosis, xenobiotic
metabolism and response to genomic damage.
The results from IPA confirmed the findings of previous works and from GSEA about an
up-regulation of antigen presentation in both IM subtypes that progress to GC, as well as
metabolism of lipids, xenobiotics and dysregulation of thyroid hormone [55] in IM not pro-
gressing to GC. New results from this analysis indicate that other transcriptional factors differ-
ent from CDX1/CDX2, such as HOXC11, could induce intestinal differentiation. HOXC11 is
an upstream regulator and other members of this family such asHOXA13, HOXB6/7/13 are
over-expressed in IM. Other new up-regulated molecular process in IM not progressing to GC
obtained from IPA is melatonin degradation.
The novelties of this study are that we analyzed both metaplasia histological subtypes that
progress or not to GC, with a high extension of the lesion (above 75% in most samples) and
performed a functional enrichment analysis based on GSEA and IPA. However, the small sam-
ple size, particularly in the CIM-GC and IIM-GC groups, is the main limitation of our study
since it reduces its power to obtain significant results after correction for multiple compari-
sons. Small sample size, together with the fact that most (75%) of the samples were reported to
be negative for H.pylori infection, was also the main reason for not performing a stratified
analysis by H.pylori infection. It is nevertheless to note that obtaining appropriate samples for
expression analysis of IM subtypes whose progression or not to GC is known from follow-up
studies is not an easy task. The results of this study are therefore a starting point for the design
of new and larger studies aimed at their validation.
To conclude, our results are the first to indicate that the transcriptional profile of IM sub-
types that progress to GC shows small differences in the gene expression levels in comparison
with those IM subtypes that do not progress. Antigen presentation and inflammation are upre-
gulated processes common to both IM histological subtypes that progress to GC but the IIM
subtype shows a higher number of up-regulated oncogenic DEGs and molecular processes
than CIM, which is in agreement with its higher risk of progression to GC.
In agreement with previous reports, the transcriptional profile of IM-NoGC with respect to
healthy mucosa evidences a drastic difference in gene expression. Apart from already reported
processes such as intestinal differentiation, metabolism of lipids and xenobiotics, new molecu-
lar processes observed in this study are non tumoral Warburg effect and melatonin degrada-
tion. Newly identified transcripts include TRIM, TMEM, homeobox genes from HOX family,
transporter genes and the small nucleolar RNAs, SNORDs116.
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